BioNTech SE ADR’s recent filing unveils that its Director Jeggle Helmut Wolfgang acquired Company’s shares for reported $14.21 million on May 07 ’25. In the deal valued at $94.74 per share,150,000 shares were bought.
Then, Richardson Ryan bought 26,500 shares, generating $3,021,000 in total proceeds.
Before that, Medine GmbH bought 1,000,000 shares. BioNTech SE ADR shares valued at $119,580,000 were divested by the Officer at a price of $119.58 per share.
Citigroup initiated its BioNTech SE ADR [BNTX] rating to a Buy in a research note published on March 13, 2025; the price target was $145. A number of analysts have revised their coverage, including Truist’s analysts, who began to cover the stock in early January with a ‘”a Buy”‘ rating. Wells Fargo began covering BNTX with “an Overweight” recommendation on December 11, 2024. BMO Capital Markets maintained its rating on December 02, 2024. It rated BNTX as “an Outperform”.
Price Performance Review of BNTX
On Tuesday, BioNTech SE ADR [NASDAQ:BNTX] saw its stock fall -2.85% to $94.50. Over the last five days, the stock has lost -0.25%. BioNTech SE ADR shares have fallen nearly -17.07% since the year began. Nevertheless, the stocks have risen 2.65% over the past one year. While a 52-week high of $131.49 was reached on 01/07/25, a 52-week low of $76.53 was recorded on 04/07/25. SMA at 50 days reached $99.23, while 200 days put it at $106.79.
Levels Of Support And Resistance For BNTX Stock
The 24-hour chart illustrates a support level at 93.44, which if violated will result in even more drops to 92.37. On the upside, there is a resistance level at 96.39. A further resistance level may holdings at 98.27. The Relative Strength Index (RSI) on the 14-day chart is 44.53, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -5.87, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 92.10%. Stochastics %K at 9.12% indicates the stock is a buying.
